ColoMARK Identification and development of novel colorectal cancer biomarkers via state-of-the-art liquid biopsy approaches
- Coordinator
- Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela, Spain
- Runs
- 1 November 2022 to 30 April 2027
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 16 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101072448
What the project is doing
In the project's own words, from its summary on CORDIS.
The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinformatics, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) that will take advantage of the assets conferred by novel liquid biopsy strategies to provide complementary and comprehensive know-how on the features required to successfully fulfil the objectives of ColoMARK: 1) to foster a next generation of scientists that can address the challenges of colorectal cancer biomarker development.
The network is enforced by pre-existing collaborations from COST Action TransColonCan, and enhanced by the participation of non-academic entities, who will play an essential role in the cross-sectoral and transversal training of the researchers. It is our purpose to provide a personalised training programme that builds on the knowledge offered by the participants to produce future cross-sectoral leadership and a sustainable initiative of excellent research that enhances the competitiveness of European researchers; 2) to achieve maximum impact by appropriate dissemination, patient and public engagement, and results exploitation, activities that will be embedded in the training of the researchers.
Given the promising perspectives of liquid biopsy approaches for the future of cancer prevention and management, ColoMARK will constitute an opportunity to reach outstanding scientific, technological and societal impact in a field highly relevant to Horizon Europe´s priorities in cancer, therefore enhancing European competitiveness in R&I; 3) to advance in colorectal cancer understanding by producing outstanding, synergistic research.
As the main scientific aim of ColoMARK, ten tailored ground-breaking research projects, only possible in the context of ColoMARK, will be undertaken for the identification and validation of better risk, prognostic and monitoring colorectal cancer biomarkers.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela | Santiago De Compostela | Spain | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| Heinrich-Heine-Universitaet Duesseldorf | Dusseldorf | Germany | Participant |
| Qiagen GmbH | Hilden | Germany | Associatedpartner |
| Destina Genomica Slne | Granada | Spain | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Servizo Galego De Saude | Santiago De Compostela | Spain | Associatedpartner |
| Universidad De Granada | Granada | Spain | Associatedpartner |
| Universidad De Santiago De Compostela | Santiago De Compostela | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Centre International De Recherche Sur Le Cancer | Lyon 7eme | France | Participant |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Participant |
| Iigm Foundation | Torino | Italy | Associatedpartner |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| GenomeScan B.V. | Leiden | Netherlands | Participant |
| European Association for Cancer Research | Nottingham | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI